Answers are grounded in this paper and cite their sources.
Alzheimer′s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, neuroinflammation, amyloid‐beta accumulation, and neuronal dysfunction. Emerging evidence suggests that the microbiota–gut–brain axis may play an important role in AD pathogenesis through interactions involving immune regulation, microbial metabolites, intestinal permeability, and neuroinflammatory pathways. Alterations in gut microbial composition have been associated with increased systemic inflammation, blood–brain barrier dysfunction, oxidative stress, and amyloid‐related pathology in both experimental and clinical studies. This narrative review summarizes current evidence regarding the relationship between gut microbiota dysbiosis and AD, with particular emphasis on mechanistic pathways, microbiota‐derived metabolites, neuroinflammation, and microbiota‐targeted therapeutic strategies. Experimental studies have demonstrated that probiotics, prebiotics, synbiotics, dietary interventions, and fecal microbiota transplantation may influence neuroinflammatory and cognitive outcomes through modulation of the gut microbiota. However, available human evidence remains limited and heterogeneous due to variations in study design, microbiome analysis methods, patient populations, and therapeutic protocols. Although growing evidence supports a potential association between gut microbiota dysbiosis and AD progression, definitive causal relationships remain incompletely understood. Further large‐scale longitudinal studies and standardized clinical trials are required to clarify the diagnostic and therapeutic potential of microbiota‐based interventions in AD management.
No takes yet. Share an insight, caveat, or question.
Ramya et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: